MedPath

The Randomized Controlled Trial Study of the Incidence of Paclitaxel Hypersensitivity Reaction as First Line drug in Gynecologic Cancer Patients between 2 Steroid Premedication Type: Hydrocortisone & dexamethasone VS Dexamethasone alone

Not Applicable
Completed
Conditions
Gynecologic cancer patients who had not been received paclitaxel therapy.Hypersensitivity reaction
Paclitaxel
hypersensitivity reaction
anaphylaxis
Premedication
Hydrocortisone
Dexamethasone
Registration Number
TCTR20151122001
Lead Sponsor
none
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
52
Inclusion Criteria

1.Gynecologic cancer patient who had pathology report
2.Need paclitaxel therapy
3.Patient who had not been received paclitaxel
4.Bone marrow, kidney,and liver were with in normal limit

Exclusion Criteria

1.allergy to hydrocortisone
2.patient who had been received paclitaxel
3.patient who had history of paclitaxel allergy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of hypersensitivity reaction during intravenous paclitaxel infusion medical record about hypersensitivity reaction during intravenous paclitaxel infusion
Secondary Outcome Measures
NameTimeMethod
none none none
© Copyright 2025. All Rights Reserved by MedPath